KALVISTA PHARMACEUTICALS INC (KALV)

US4834971032 - Common Stock

8.76  -0.07 (-0.79%)

After market: 8.8 +0.04 (+0.46%)

Fundamental Rating

2

Taking everything into account, KALV scores 2 out of 10 in our fundamental rating. KALV was compared to 565 industry peers in the Biotechnology industry. While KALV has a great health rating, there are worries on its profitability. KALV is valued expensive and it does not seem to be growing.



Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year KALV has reported negative net income.
In the past year KALV has reported a negative cash flow from operations.
KALV had negative earnings in each of the past 5 years.
In the past 5 years KALV always reported negative operating cash flow.

1.2 Ratios

The Return On Assets of KALV (-97.24%) is worse than 75.62% of its industry peers.
KALV has a Return On Equity (-116.71%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -97.24%
ROE -116.71%
ROIC N/A
ROA(3y)-48.3%
ROA(5y)-38.68%
ROE(3y)-54.5%
ROE(5y)-43.24%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for KALV so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

More info and screens

7

2. Health

2.1 Basic Checks

The number of shares outstanding for KALV has been increased compared to 1 year ago.
Compared to 5 years ago, KALV has more shares outstanding
There is no outstanding debt for KALV. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

KALV has an Altman-Z score of 2.32. This is not the best score and indicates that KALV is in the grey zone with still only limited risk for bankruptcy at the moment.
The Altman-Z score of KALV (2.32) is better than 72.60% of its industry peers.
There is no outstanding debt for KALV. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 2.32
ROIC/WACCN/A
WACCN/A

2.3 Liquidity

A Current Ratio of 6.87 indicates that KALV has no problem at all paying its short term obligations.
KALV's Current ratio of 6.87 is fine compared to the rest of the industry. KALV outperforms 66.90% of its industry peers.
A Quick Ratio of 6.87 indicates that KALV has no problem at all paying its short term obligations.
With a decent Quick ratio value of 6.87, KALV is doing good in the industry, outperforming 67.08% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 6.87
Quick Ratio 6.87

More info and screens

1

3. Growth

3.1 Past

The earnings per share for KALV have decreased strongly by -18.95% in the last year.
EPS 1Y (TTM)-18.95%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-13.75%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 21.66% on average over the next years. This is a very strong growth
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-10.4%
EPS Next 2Y10.59%
EPS Next 3Y20.49%
EPS Next 5Y21.66%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

KALV reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year KALV is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as KALV's earnings are expected to grow with 20.49% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y10.59%
EPS Next 3Y20.49%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for KALV!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

KALVISTA PHARMACEUTICALS INC

NASDAQ:KALV (12/24/2024, 8:23:54 PM)

After market: 8.8 +0.04 (+0.46%)

8.76

-0.07 (-0.79%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)12-05 2024-12-05/bmo
Earnings (Next)N/A N/A
Inst Owners111.65%
Inst Owner Change0.53%
Ins Owners1.63%
Ins Owner Change10.22%
Market Cap432.92M
Analysts86.15
Price Target29.75 (239.61%)
Short Float %16.58%
Short Ratio21.18
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)4.21%
Min EPS beat(2)1.74%
Max EPS beat(2)6.68%
EPS beat(4)2
Avg EPS beat(4)-8.9%
Min EPS beat(4)-36.67%
Max EPS beat(4)6.68%
EPS beat(8)6
Avg EPS beat(8)3.13%
EPS beat(12)10
Avg EPS beat(12)5.59%
EPS beat(16)13
Avg EPS beat(16)4.57%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-3.31%
PT rev (3m)-0.11%
EPS NQ rev (1m)27.18%
EPS NQ rev (3m)27.18%
EPS NY rev (1m)-24.16%
EPS NY rev (3m)1.78%
Revenue NQ rev (1m)2058.47%
Revenue NQ rev (3m)2058.47%
Revenue NY rev (1m)-100%
Revenue NY rev (3m)-100%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 3.23
P/tB 3.23
EV/EBITDA N/A
EPS(TTM)-3.64
EYN/A
EPS(NY)-2.64
Fwd EYN/A
FCF(TTM)-2.49
FCFYN/A
OCF(TTM)-2.48
OCFYN/A
SpS0
BVpS2.71
TBVpS2.71
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -97.24%
ROE -116.71%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-48.3%
ROA(5y)-38.68%
ROE(3y)-54.5%
ROE(5y)-43.24%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 59.18%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.87
Quick Ratio 6.87
Altman-Z 2.32
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)129.01%
Cap/Depr(5y)89%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-18.95%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-13.75%
EPS Next Y-10.4%
EPS Next 2Y10.59%
EPS Next 3Y20.49%
EPS Next 5Y21.66%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-46.05%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-43.77%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-45.55%
OCF growth 3YN/A
OCF growth 5YN/A